Clinical Takeda Pharmaceutical gets FDA nod for lung cancer drug...

Takeda Pharmaceutical gets FDA nod for lung cancer drug Exkivity

-

The U.S. Food and Drug Administration had approved Takeda Pharmaceutical Co.’s drug, Exkivity, to treat a particular type of lung cancer, the Japanese pharmaceutical company announced on 15th September.

The drug has been approved only for patients having a particular gene mutation in non-small cell lung cancer (NSCLC) known as EGFR Exon 20 insertion, whose disease has grown during or after the chemotherapy.   

Exkivity’s approval from the FDA was explicitly based on some affirmative and meaningful results yielded from early-to-mid stage trials carried out on 114 patients having NSCLC, over a period of 18 months on average, the company said, which is subjected to the verification and description of clinical benefit through confirmatory trials.

However, the drug is marketed with a boxed warning indicating potential risks relating to the heart toxicity, heart rhythm disturbance and lung diseases.

According to the World Health Organization, NSCLC is the most common type of lung cancer constituting up to 85% of the estimated 2.2 million cases of lung cancer diagnosed every year globally.   

+ posts

Latest news

AstraZeneca’s Obesity Pill Shows Positive Results in Early Trial

AstraZeneca announced that its new weight-loss medication, which was licensed from Eccogene of China, underwent early-stage testing and was...

Novo scores license to use Ascendis’ TransCon platform for $285 million

In exchange for $285 million, Copenhagen-based Ascendis has agreed to help Novo Nordisk develop a once-a-month GLP-1 receptor antagonist...

Apellis and Novartis both target rare kidney diseases with new drugs

Apellis Pharmaceuticals and Novartis recently shared data for their rare kidney disease drugs, pegcetacoplan and iptacopan. Both have performed...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you